Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haem arginate: a new stable haem compound.

R Tenhunen1, O Tokola, I B Lindén

  • 1Department of Clinical Chemistry, University Central Hospital of Helsinki, Finland.

The Journal of Pharmacy and Pharmacology
|October 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticonvulsant activity of 2-phthalimidoethanesulphonamides: New derivatives of taurine.

Neurochemistry international·2010
Same author

[Drug regulatory agency comments on the editorial about the new influenza drugs].

Duodecim; laaketieteellinen aikakauskirja·2002
Same author

L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.

Psychopharmacology·2001
Same author

Expression and characterization of six mutations in the protoporphyrinogen oxidase gene among Finnish variegate porphyria patients.

Molecular medicine (Cambridge, Mass.)·2001
Same author

Homozygous variegate porphyria: 20 y follow-up and characterization of molecular defect.

The Journal of investigative dermatology·2001
Same author

Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.

Journal of neural transmission (Vienna, Austria : 1996)·2001

A new stable haem preparation, haem arginate, effectively treats experimental porphyria and shows promise for acute hepatic porphyrias. This stable haem compound offers a potential improvement over unstable haematin therapies.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hepatology

Background:

  • Acute hepatic porphyrias result from haem deficiency, leading to toxic metabolite accumulation.
  • Current haem therapy uses haematin, which is unstable and can cause adverse reactions.
  • A need exists for a stable, effective, and well-tolerated haem preparation.

Purpose of the Study:

  • To develop and evaluate a stable haem compound for treating acute hepatic porphyrias.
  • To compare the stability and efficacy of haem arginate with conventional haematin.

Main Methods:

  • Haem arginate was synthesized from human blood-derived haemin.
  • Haem derivatives were screened as haem oxygenase substrates.
  • Stability of haem arginate solutions was assessed over time and compared to haematin.

Related Experiment Videos

  • Antiporphyrogenic effects were evaluated in a rat model of experimental porphyria.

    • Main Results:

    • Haem arginate demonstrated stability for up to 2 years at +6°C.
    • Haem arginate solutions were significantly more stable than haematin solutions.
    • Haem arginate showed an antiporphyrogenic effect comparable to fresh haematin in vivo.
    • Low acute oral toxicity was observed, indicating poor oral bioavailability.

    Conclusions:

    • Haem arginate is a stable and effective haem preparation.
    • It shows comparable efficacy to haematin in experimental models.
    • Haem arginate represents a promising alternative to unstable haematin for treating porphyrias.